Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer

Prostate Cancer and Prostatic Diseases volume 11, pages 166–172 (2008)Cite this article

Abstract

The molecular mechanisms for hormone-resistant prostate cancer progression still remain elusive, mainly due to the limited availability of corresponding tissue. As transurethral resection (TUR) is a common palliative therapy for patients with hormone refractory prostate cancer (HRPC) who have subvesical obstruction, we aimed to demonstrate that TUR samples can be used to identify significantly affected biological pathways during the switch to HRPC using oligonucleotide microarray analysis. Among the most significantly deregulated pathways in HRPC, we observed an induction of oxidative phosphorylation and a repression of cytoskeletal components.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. Gronberg H . Prostate cancer epidemiology. Lancet 2003; 361: 859–864.

    Google Scholar 

  2. Isaacs JT . The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999; 26: 263–273.

    Article  CAS  PubMed  Google Scholar 

  3. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54: 5474–5478.

    CAS  PubMed  Google Scholar 

  4. Liu Y, Majumder S, McCall W, Sartor CI, Mohler JL, Gregory CW et al. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 2005; 65: 3404–3409.

    Article  CAS  PubMed  Google Scholar 

  5. Zhang F, Lee J, Lu S, Pettaway CA, Dong Z . Blockade of transforming growth factor-beta signalling suppresses progression of androgen-independent human prostate cancer in nude mice. Clin Cancer Res 2005; 11: 4512–4520.

    Article  CAS  PubMed  Google Scholar 

  6. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 2004; 101: 9309–9314.

    Article  CAS  PubMed  Google Scholar 

  7. Best CJM, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y et al. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 2005; 11: 6823–6834.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164: 217–227.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Scher HI, Steineck G, Kelly WK . Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995; 46: 142–148.

    Article  CAS  PubMed  Google Scholar 

  10. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP . Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003; 31: e15.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Mansmann U, Meister R . Testing differential gene expression in functional groups. Goeman's global test versus an ANCOVA approach. Methods Inf Med 2005; 44: 449–453.

    Article  CAS  PubMed  Google Scholar 

  12. Van der Laan M, Pollard K . A new algorithm for hybrid hierarchical clustering with visualization and the bootstrap. J Stat Plan Inter 2003; 117: 275–303.

    Article  Google Scholar 

  13. Goeman JJ, Oosting J, Cleton-Jansen AM, Anninga JK, van Houwelingen HC . A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 2004; 201: 93–99.

    Article  Google Scholar 

  14. Benjamini Y, Hochberg Y . Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 1995; 57: 289–300.

    Google Scholar 

  15. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004; 22: 2790–2799.

    Article  CAS  PubMed  Google Scholar 

  16. Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ, Capaldi RA . Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res 2004; 64: 985–993.

    Article  CAS  PubMed  Google Scholar 

  17. Choi JK, Yu U, Yoo OJ, Kim S . Differential coexpression analysis using microarray data and its application to human cancer. Bioinformatics 2005; 21: 4348–4355.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research study was supported by a Research Grant of Novartis Oncology. We thank Karen Czeloth for critically reviewing this manuscript.

Author information

Authors and Affiliations

  1. TARGOS Molecular Pathology GmbH, Kassel, Germany

    O Stoss, D Zielinski, J Rüschoff & T Henkel

  2. Institute of Pathology and Biomedical Research, Klinikum Kassel GmbH, Kassel, Germany

    M Werther, P Middel & J Rüschoff

  3. Department of Urology, Klinikum Kassel GmbH, Kassel, Germany

    N Jost & P Albers

Authors
  1. O Stoss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Werther
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Zielinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Middel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N Jost
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Rüschoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Henkel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P Albers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O Stoss.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stoss, O., Werther, M., Zielinski, D. et al. Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer. Prostate Cancer Prostatic Dis 11, 166–172 (2008). https://doi.org/10.1038/sj.pcan.4501001

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4501001

Keywords

This article is cited by

Search

Advanced search

Quick links